نتایج جستجو برای: rank ligand

تعداد نتایج: 178783  

Journal: :Journal of immunology 2010
Changzhen Liu Thomas S Walter Peng Huang Shiqian Zhang Xuekai Zhu Ying Wu Lucy R Wedderburn Peifu Tang Raymond J Owens David I Stuart Jingshan Ren Bin Gao

Bone remodeling involves bone resorption by osteoclasts and synthesis by osteoblasts and is tightly regulated by the receptor activator of the NF-kappaB ligand (RANKL)/receptor activator of the NF-kappaB (RANK)/osteoprotegerin molecular triad. RANKL, a member of the TNF superfamily, induces osteoclast differentiation, activation and survival upon interaction with its receptor RANK. The decoy re...

Journal: :Arteriosclerosis, Thrombosis, and Vascular Biology 2006

پایان نامه :دانشگاه آزاد اسلامی - دانشگاه آزاد اسلامی واحد تهران مرکزی - دانشکده علوم پایه 1390

abstract the cr(iii) and zn(ii) complexes with 2-((9,10-dihydro-1-hydroxy-9,10-dioxaanthracen-4-yloxy)carbonyl)benzoic acid as ligand have been prepared by reacting cr(no3) and zn(no3)2 and ligand in cloroform. the cr and zn complexes with 2-((9,10-dihydro-1-hydroxy-9,10-dioxaanthracen-4-yloxy)carbonyl) were also prepared in chloroform and aceton solutions. the uv-visible and ft-ir spectra of...

Journal: :Acta crystallographica. Section F, Structural biology and crystallization communications 2009
Thomas S Walter Changzhen Liu Peng Huang Shiqian Zhang Lucy R Wedderburn Bin Gao Raymond J Owens David I Stuart Peifu Tang Jingshan Ren

The interaction between the TNF-family molecule receptor activator of NF-kappaB ligand (RANKL) and its receptor RANK induces osteoclast formation, activation and survival in the process of bone remodelling. RANKL-RANK also plays critical roles in T-cell/dendritic cell communication and lymph-node formation and in a variety of pathologic conditions such as tumour-cell migration and bone metastas...

Journal: :British journal of pharmacology 2012
Olivier Micheau Florent Dufour Henning Walczak

Metastatic bone disease is a serious clinical complication for the treatment of patients with advanced cancer, but few therapeutic options are currently available. Bisphosphonates are an established standard care for these patients, but new treatments are now emerging, including the use of monoclonal antibodies targeting the RANK ligand. In this issue of the BJP, Reuter et al. provide evidence ...

Journal: :Arthritis Research 2000
Sophie Roux Philippe Orcel

Osteoclast activation is a critical cellular process for pathological bone resorption, such as erosions in rheumatoid arthritis (RA) or generalized bone loss. Among many factors triggering excessive osteoclast activity, cytokines such as IL-1 or tumour necrosis factor (TNF)-alpha play a central role. New members of the TNF receptor ligand family (namely receptor activator of nuclear factor-kapp...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید